An article by BRMI Medical Director James Odell, ND, OMD, LAc, appears in this month's Townsend Letter - entitled "Globulin Component Macrophage Activating Factor (GcMAF) Immunotherapy". Click here to access the article - and learn how GcMAF activates tumoricidal macrophages, leading to tumor regression.